Sign In
Buy SGPYY
$42.52
+0.0600 (+0.141%)
At Close: Jun 23, 2026
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag
05:34am, Wednesday, 09'th Apr 2025
Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals
UK's Sage Group says Cartin to replace Howell as CFO next year
03:52am, Thursday, 27'th Mar 2025
British software firm Sage Group named Jacqui Cartin as its new chief financial officer on Thursday, succeeding Jonathan Howell, who will leave on December 31.
Greenbriar Completes Major Water Acquisition for Sage Ranch
09:00am, Monday, 17'th Mar 2025
Scottsdale, Arizona--(Newsfile Corp. - March 17, 2025) - Greenbriar Sustainable Living Inc. (TSXV: GRB) (OTC Pink: GEBRF) ("Greenbriar" or the "Company") is pleased to announce that it has reached a b
Sage Therapeutics Announces R&D Leadership Transition
04:15pm, Tuesday, 04'th Mar 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Compa
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
12:46pm, Wednesday, 12'th Feb 2025
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
04:05pm, Tuesday, 11'th Feb 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. “We
Sage Potash Closes C$2.5 Million Private Placement
07:20pm, Tuesday, 04'th Feb 2025
VANCOUVER, BC , Feb. 4, 2025 /PRNewswire/ - Sage Potash Corp. (TSXV: SAGE) (OTC: SGPTF) ("Sage" or the "Company") is pleased to announce that it has closed its non-brokered private placement of comm
The Sage Group plc (SGGEF) Q1 2025 Earnings Call Transcript
08:39am, Thursday, 30'th Jan 2025
The Sage Group plc (OTCPK:SGGEF) Q1 2025 Earnings Conference Call January 30, 2024 3:30 AM ET Company Participants Jonathan Howell - CFO Conference Call Participants Adam Wood - Morgan Stanley Toby Og
Sage rejects Biogen's $469 million takeover offer
09:28am, Monday, 27'th Jan 2025
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) (“Sage” or “the Company”), today announced that its Board of Directors has initiated a process to explore strategic al
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm
01:38pm, Friday, 24'th Jan 2025
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE) breach
According to THE SAGE GROUP, Over 3.5 Million Critical Limb Ischemia (CLI) Patients Have Calcified Lower Limb Arteries
11:56am, Wednesday, 15'th Jan 2025
BEAUFORT, S.C.--(BUSINESS WIRE)-- #CLIFighters--A new report published by THE SAGE GROUP reviews recent calcium research and quantifies the number of CLI patients with calcified leg arteries. “Almos
Sage Therapeutics shares surge on unsolicited takeover bid from Biogen
11:51am, Monday, 13'th Jan 2025
Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB, ETR:IDP). Biogen has proposed to acquire all of S
Sage Therapeutics Stock Headed for Best Day in 5 Years
11:16am, Monday, 13'th Jan 2025
Biotech stock Sage Therapeutics Inc (NASDAQ:SAGE) is skyrocketing today, up 33.7% to trade at $7.42 at last glance, after Biogen's (BIIB) proposed takeover, which the company said on Friday it would c
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
10:40am, Monday, 13'th Jan 2025
Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.
